Supporting oncology professionals through education
The content on this site is intended for healthcare professionals only
The content on this site is intended for healthcare professionals only
Dr Enrique Grande (MD Anderson Cancer Center Madrid, Madrid, Spain), Prof Syed Hussain (The University of Sheffield, Sheffield, UK), Dr Patrizia Giannatempo (Istituto Nazionale dei Tumori, Milan, Italy) and Dr Félix Guerrero-Ramos (Hospital Universitario 12 de Octubre, Madrid, Spain) discuss the latest in precision medicine in bladder cancer.
The panel explores recent clinical data demonstrating advances in personalised therapy and examines how modern treatment sequencing—including neoadjuvant, adjuvant, and maintenance strategies are evolving to improve outcomes.
The discussion focuses on optimising second-line and later treatment options to maximise patient benefit, with an emphasis on the growing real-world impact of biomarker-driven decision-making.
The panel also highlights emerging therapies and innovative combination regimens designed to enhance efficacy while preserving patient quality of life.
| Disitamab vedotin (DV) plus toripalimab (T) versus chemotherapy (C) in first-line (1L) locally advanced or metastatic urothelial carcinoma (la/mUC) with HER2-expression | |
| JAVELIN bladder medley phase II trial of avelumab + sacituzumab govitecan (Ave + SG) vs avelumab monotherapy (Ave mono) as first-line (1L) maintenance treatment for advanced urothelial carcinoma (aUC): Subgroup analyses based on metastatic sites | |
| Perioperative (periop) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants (pts) with muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible: The phase III KEYNOTE-905 study | |
| IMvigor011: A phase III trial of circulating tumour (ct)DNA-guided adjuvant atezolizumab vs placebo in muscle-invasive bladder cancer | |
| Neoadjuvant gemcitabine intravesical system (TAR-200) + cetrelimab (CET) or CET alone in patients (pts) with muscle-invasive bladder cancer (MIBC): SunRISe-4 (SR-4) primary analysis and biomarker results | |
| Association of molecular markers with clinical response to TAR-200 in the phase IIb SunRISe-1 trial in patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary disease | |
| POTOMAC, CREST and ALBAN trials |
